Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Phase 2 Recruiting
120 enrolled
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Phase 1 Recruiting
24 enrolled
OPTION-DDR
Phase 3 Recruiting
236 enrolled
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Phase 3 Recruiting
750 enrolled
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Phase 2/3 Recruiting
613 enrolled
ADAPT-BLADDER
Phase 1/2 Recruiting
55 enrolled
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/2 Recruiting
398 enrolled
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Phase 3 Recruiting
320 enrolled
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Phase 1/2 Recruiting
99 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
Phase 3 Recruiting
460 enrolled
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Phase 1/2 Recruiting
98 enrolled
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
698 enrolled
LuCa-MERIT-1
Phase 1 Recruiting
320 enrolled
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
PRESERVE-003
Phase 3 Recruiting
630 enrolled
TRIPLE-SWITCH
Phase 3 Recruiting
830 enrolled
KLK2-PASenger
Phase 3 Recruiting
800 enrolled
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Phase 2 Recruiting
20 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Phase 1 Recruiting
300 enrolled
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Phase 1/2 Recruiting
74 enrolled
IDeate-Prostate02
Phase 1/2 Recruiting
360 enrolled
MK-2400-001
Phase 3 Recruiting
1,440 enrolled
TroFuse-033
Phase 3 Recruiting
1,123 enrolled
TroFuse-031
Phase 3 Recruiting
590 enrolled
NSCLC
Phase 3 Recruiting
536 enrolled
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
Phase 1/2 Recruiting
86 enrolled
DE-01
Phase 3 Recruiting
600 enrolled
InavoPC
Phase 2 Recruiting
100 enrolled
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Phase 3 Recruiting
1,800 enrolled
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
Phase 2 Recruiting
63 enrolled
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3 Recruiting
1,100 enrolled
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Phase 3 Recruiting
1,260 enrolled
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Phase 3 Recruiting
300 enrolled
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Phase 2 Recruiting
146 enrolled
IMMUNOLIFE2
Phase 2 Recruiting
162 enrolled
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Phase 2 Recruiting
34 enrolled
ARTEMIA
Phase 3 Recruiting
363 enrolled
MK-3475-01I
Phase 2 Recruiting
144 enrolled
Fern-EC-01
Phase 3 Recruiting
480 enrolled
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Phase 1 Recruiting
40 enrolled
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Phase 1/2 Recruiting
40 enrolled
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Phase 1 Recruiting
288 enrolled
CAMPFIRE
Phase 2 Recruiting
105 enrolled
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Phase 2 Recruiting
70 enrolled
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Phase 3 Recruiting
544 enrolled
MK-5684-01A
Phase 1/2 Recruiting
220 enrolled
ctDNA in HER2+ EBC Neoadjuvant Treatment
Phase 2 Recruiting
60 enrolled
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Phase 2 Recruiting
82 enrolled